MovDisordV3, PascalFrancis, Curation, bibRecord, 002C42

Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease

Identifieur interne : 002C42 ( PascalFrancis/Curation ); précédent : 002C41; suivant : 002C43

Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease

Auteurs : Bernard Ravina [États-Unis] ; Kenneth Marek [États-Unis] ; Shirley Eberly [États-Unis] ; David Oakes [États-Unis] ; Roger Kurlan [États-Unis] ; Alberto Ascherio [États-Unis] ; Flint Beal [États-Unis] ; James Beck [États-Unis] ; Emily Flagg [États-Unis] ; Wendy R. Galpern [États-Unis] ; Jennifer Harman [États-Unis] ; Anthony E. Lang [Canada] ; Michael Schwarzschild [États-Unis] ; Caroline Tanner [États-Unis] ; Ira Shoulson [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0393087

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Dopamine, Long terme, Pronostic.

English descriptors

KwdEn :
- Dopamine, Long term, Nervous system diseases, Parkinson disease, Prognosis.

Abstract

Dopamine (DA) transporter (DAT) imaging has been studied as a diagnostic tool for degenerative parkinsonism. Our aim was to measure the prognostic value of imaging for motor and nonmotor outcomes in Parkinson's disease (PD). We prospectively evaluated a Parkinson's cohort after enrollment in a de novo clinical trial with a battery of motor (UPDRS), cognitive (Montreal Cognitive Assessment), and behavioral measures. DAT imaging with [¹²³I][β]-CIT and single-photon emission computerized tomography (SPECT) was performed at baseline and after 22 months. In total, 491 (91 %) of the 537 subjects had evidence of DA deficiency on their baseline scan, consistent with PD, and were included in the analyses. The cohort was followed for 5.5 (0.8) years, with a mean duration of diagnosis of 6.3 (1.2). Lower striatal binding at baseline was independently associated with higher risk for clinical milestones and measures of disease severity, including motorrelated disability, falling and postural instability, cognitive impairment, psychosis, and clinically important depressive symptoms. Subjects in the bottom quartile for striatal binding, compared to the top quartile, had an odds ratio (95% confidence interval) of 3.3 (1.7, 6.7) for cognitive impairment and 12.9 (2.6, 62.4) for psychosis. Change from baseline in imaging after 22 months was also independently associated with motor, cognitive, and behavioral outcomes. DAT imaging with [¹²³I][β]-CIT and SPECT, shortly after the diagnosis of PD, was independently associated with clinically important long-term motor and nonmotor outcomes. These results should be treated as hypothesis generating and require confirmation.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 27`
A06				`@2 11`
A08	`01`	`1`	`ENG`	`@1 Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease`
A11	`01`	`1`		`@1 RAVINA (Bernard)`
A11	`02`	`1`		`@1 MAREK (Kenneth)`
A11	`03`	`1`		`@1 EBERLY (Shirley)`
A11	`04`	`1`		`@1 OAKES (David)`
A11	`05`	`1`		`@1 KURLAN (Roger)`
A11	`06`	`1`		`@1 ASCHERIO (Alberto)`
A11	`07`	`1`		`@1 BEAL (Flint)`
A11	`08`	`1`		`@1 BECK (James)`
A11	`09`	`1`		`@1 FLAGG (Emily)`
A11	`10`	`1`		`@1 GALPERN (Wendy R.)`
A11	`11`	`1`		`@1 HARMAN (Jennifer)`
A11	`12`	`1`		`@1 LANG (Anthony E.)`
A11	`13`	`1`		`@1 SCHWARZSCHILD (Michael)`
A11	`14`	`1`		`@1 TANNER (Caroline)`
A11	`15`	`1`		`@1 SHOULSON (Ira)`
A14	`01`			`@1 Biogen Idec @2 Cambridge, Massachusetts @3 USA @Z 1 aut. @Z 9 aut. @Z 15 aut.`
A14	`02`			`@1 Institute for Neurodegenerative Disorders @2 New Haven, Connecticut @3 USA @Z 2 aut.`
A14	`03`			`@1 University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 3 aut. @Z 4 aut. @Z 11 aut.`
A14	`04`			`@1 Atlantic Neuroscience Institute @2 Summit, New Jersey @3 USA @Z 5 aut.`
A14	`05`			`@1 Massachusetts General Hospital @2 Boston, Massachusetts @3 USA @Z 6 aut. @Z 13 aut.`
A14	`06`			`@1 Cornell University School of Medicine @2 New York, New York @3 USA @Z 7 aut.`
A14	`07`			`@1 The Parkinson's Disease Foundation @2 New York, New York @3 USA @Z 8 aut.`
A14	`08`			`@1 The National Institute of Neurological Disorders and Stroke @2 , Bethesda, Maryland @3 USA @Z 10 aut.`
A14	`09`			`@1 The University of Toronto @2 Toronto, Ontario @3 CAN @Z 12 aut.`
A14	`10`			`@1 The Parkinson's Institute @2 Sunnyvale, California @3 USA @Z 14 aut.`
A20				`@1 1392-1397`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000502036870140`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 30 ref.`
A47	`01`	`1`		`@0 12-0393087`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Dopamine (DA) transporter (DAT) imaging has been studied as a diagnostic tool for degenerative parkinsonism. Our aim was to measure the prognostic value of imaging for motor and nonmotor outcomes in Parkinson's disease (PD). We prospectively evaluated a Parkinson's cohort after enrollment in a de novo clinical trial with a battery of motor (UPDRS), cognitive (Montreal Cognitive Assessment), and behavioral measures. DAT imaging with [¹²³I][β]-CIT and single-photon emission computerized tomography (SPECT) was performed at baseline and after 22 months. In total, 491 (91 %) of the 537 subjects had evidence of DA deficiency on their baseline scan, consistent with PD, and were included in the analyses. The cohort was followed for 5.5 (0.8) years, with a mean duration of diagnosis of 6.3 (1.2). Lower striatal binding at baseline was independently associated with higher risk for clinical milestones and measures of disease severity, including motorrelated disability, falling and postural instability, cognitive impairment, psychosis, and clinically important depressive symptoms. Subjects in the bottom quartile for striatal binding, compared to the top quartile, had an odds ratio (95% confidence interval) of 3.3 (1.7, 6.7) for cognitive impairment and 12.9 (2.6, 62.4) for psychosis. Change from baseline in imaging after 22 months was also independently associated with motor, cognitive, and behavioral outcomes. DAT imaging with [¹²³I][β]-CIT and SPECT, shortly after the diagnosis of PD, was independently associated with clinically important long-term motor and nonmotor outcomes. These results should be treated as hypothesis generating and require confirmation.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Long terme @5 10`
C03	`04`	`X`	`ENG`	`@0 Long term @5 10`
C03	`04`	`X`	`SPA`	`@0 Largo plazo @5 10`
C03	`05`	`X`	`FRE`	`@0 Pronostic @5 11`
C03	`05`	`X`	`ENG`	`@0 Prognosis @5 11`
C03	`05`	`X`	`SPA`	`@0 Pronóstico @5 11`
C07	`01`	`X`	`FRE`	`@0 Catécholamine @5 37`
C07	`01`	`X`	`ENG`	`@0 Catecholamine @5 37`
C07	`01`	`X`	`SPA`	`@0 Catecolamina @5 37`
C07	`02`	`X`	`FRE`	`@0 Neurotransmetteur @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurotransmitter @5 38`
C07	`02`	`X`	`SPA`	`@0 Neurotransmisor @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 42`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
N21				`@1 303`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000072

Links to Exploration step

Pascal:12-0393087

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease</title>
<author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Biogen Idec</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Atlantic Neuroscience Institute</s1>
<s2>Summit, New Jersey</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Beal, Flint" sort="Beal, Flint" uniqKey="Beal F" first="Flint" last="Beal">Flint Beal</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Cornell University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Beck, James" sort="Beck, James" uniqKey="Beck J" first="James" last="Beck">James Beck</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>The Parkinson's Disease Foundation</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Biogen Idec</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>The National Institute of Neurological Disorders and Stroke</s1>
<s2>, Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Harman, Jennifer" sort="Harman, Jennifer" uniqKey="Harman J" first="Jennifer" last="Harman">Jennifer Harman</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>The University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Schwarzschild, Michael" sort="Schwarzschild, Michael" uniqKey="Schwarzschild M" first="Michael" last="Schwarzschild">Michael Schwarzschild</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Biogen Idec</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0393087</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0393087 INIST</idno>
<idno type="RBID">Pascal:12-0393087</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000072</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002C42</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease</title>
<author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Biogen Idec</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Kurlan, Roger" sort="Kurlan, Roger" uniqKey="Kurlan R" first="Roger" last="Kurlan">Roger Kurlan</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Atlantic Neuroscience Institute</s1>
<s2>Summit, New Jersey</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Beal, Flint" sort="Beal, Flint" uniqKey="Beal F" first="Flint" last="Beal">Flint Beal</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Cornell University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Beck, James" sort="Beck, James" uniqKey="Beck J" first="James" last="Beck">James Beck</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>The Parkinson's Disease Foundation</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Flagg, Emily" sort="Flagg, Emily" uniqKey="Flagg E" first="Emily" last="Flagg">Emily Flagg</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Biogen Idec</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Galpern, Wendy R" sort="Galpern, Wendy R" uniqKey="Galpern W" first="Wendy R." last="Galpern">Wendy R. Galpern</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>The National Institute of Neurological Disorders and Stroke</s1>
<s2>, Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Harman, Jennifer" sort="Harman, Jennifer" uniqKey="Harman J" first="Jennifer" last="Harman">Jennifer Harman</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>The University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Schwarzschild, Michael" sort="Schwarzschild, Michael" uniqKey="Schwarzschild M" first="Michael" last="Schwarzschild">Michael Schwarzschild</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Biogen Idec</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term>
<term>Long term</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prognosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Dopamine</term>
<term>Long terme</term>
<term>Pronostic</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopamine (DA) transporter (DAT) imaging has been studied as a diagnostic tool for degenerative parkinsonism. Our aim was to measure the prognostic value of imaging for motor and nonmotor outcomes in Parkinson's disease (PD). We prospectively evaluated a Parkinson's cohort after enrollment in a de novo clinical trial with a battery of motor (UPDRS), cognitive (Montreal Cognitive Assessment), and behavioral measures. DAT imaging with [<sup>123</sup>
I][β]-CIT and single-photon emission computerized tomography (SPECT) was performed at baseline and after 22 months. In total, 491 (91 %) of the 537 subjects had evidence of DA deficiency on their baseline scan, consistent with PD, and were included in the analyses. The cohort was followed for 5.5 (0.8) years, with a mean duration of diagnosis of 6.3 (1.2). Lower striatal binding at baseline was independently associated with higher risk for clinical milestones and measures of disease severity, including motorrelated disability, falling and postural instability, cognitive impairment, psychosis, and clinically important depressive symptoms. Subjects in the bottom quartile for striatal binding, compared to the top quartile, had an odds ratio (95% confidence interval) of 3.3 (1.7, 6.7) for cognitive impairment and 12.9 (2.6, 62.4) for psychosis. Change from baseline in imaging after 22 months was also independently associated with motor, cognitive, and behavioral outcomes. DAT imaging with [<sup>123</sup>
I][β]-CIT and SPECT, shortly after the diagnosis of PD, was independently associated with clinically important long-term motor and nonmotor outcomes. These results should be treated as hypothesis generating and require confirmation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RAVINA (Bernard)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MAREK (Kenneth)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>EBERLY (Shirley)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>OAKES (David)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KURLAN (Roger)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ASCHERIO (Alberto)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BEAL (Flint)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BECK (James)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>FLAGG (Emily)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GALPERN (Wendy R.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>HARMAN (Jennifer)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SCHWARZSCHILD (Michael)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>TANNER (Caroline)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>SHOULSON (Ira)</s1>
</fA11>
<fA14 i1="01"><s1>Biogen Idec</s1>
<s2>Cambridge, Massachusetts</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>New Haven, Connecticut</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Atlantic Neuroscience Institute</s1>
<s2>Summit, New Jersey</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Massachusetts General Hospital</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Cornell University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>The Parkinson's Disease Foundation</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>The National Institute of Neurological Disorders and Stroke</s1>
<s2>, Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>The University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>The Parkinson's Institute</s1>
<s2>Sunnyvale, California</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA20><s1>1392-1397</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000502036870140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0393087</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Dopamine (DA) transporter (DAT) imaging has been studied as a diagnostic tool for degenerative parkinsonism. Our aim was to measure the prognostic value of imaging for motor and nonmotor outcomes in Parkinson's disease (PD). We prospectively evaluated a Parkinson's cohort after enrollment in a de novo clinical trial with a battery of motor (UPDRS), cognitive (Montreal Cognitive Assessment), and behavioral measures. DAT imaging with [<sup>123</sup>
I][β]-CIT and single-photon emission computerized tomography (SPECT) was performed at baseline and after 22 months. In total, 491 (91 %) of the 537 subjects had evidence of DA deficiency on their baseline scan, consistent with PD, and were included in the analyses. The cohort was followed for 5.5 (0.8) years, with a mean duration of diagnosis of 6.3 (1.2). Lower striatal binding at baseline was independently associated with higher risk for clinical milestones and measures of disease severity, including motorrelated disability, falling and postural instability, cognitive impairment, psychosis, and clinically important depressive symptoms. Subjects in the bottom quartile for striatal binding, compared to the top quartile, had an odds ratio (95% confidence interval) of 3.3 (1.7, 6.7) for cognitive impairment and 12.9 (2.6, 62.4) for psychosis. Change from baseline in imaging after 22 months was also independently associated with motor, cognitive, and behavioral outcomes. DAT imaging with [<sup>123</sup>
I][β]-CIT and SPECT, shortly after the diagnosis of PD, was independently associated with clinically important long-term motor and nonmotor outcomes. These results should be treated as hypothesis generating and require confirmation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Long terme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Long term</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fN21><s1>303</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C42 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002C42 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0393087
   |texte=   Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease

Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri